The Thesis
Certara is a biosimulation software company that helps drugmakers model how new medicines interact with the human body through virtual trials. The company generated $390 million in revenue in 2024, representing 11% growth over the previous year. The structural shift toward biosimulation as a regulatory requirement by the FDA and global agencies is what makes the rest of the growth story possible.
If you own CERT, you're betting on three specific things.
In our view, the market is significantly underestimating how critical Certara's software has become to the drug approval process. We think the company is a multi-year compounder driven by the inevitable transition from physical to virtual drug testing. The case breaks if software sales stagnate or if a major competitor like Simulations Plus begins winning share at the top tier of the market. For long-term investors, Certara is one of the cleaner ways to own the digitization of healthcare.
Numbers at a Glance
What does it do?
Certara is a growth-stage business that earns money by selling specialized software and expert consulting to help pharmaceutical companies predict how drugs will perform. Drug developers use Certara's biosimulation tools to run virtual trials, which helps them decide the right dosage and predict side effects before testing on humans. This process saves drugmakers millions of dollars by failing bad drugs early and optimizing the ones that work. Customers pay through multi-year software licenses or by hiring Certara’s scientists for specific drug development projects.
Where does revenue come from?
Revenue is split between high-margin software subscriptions and technology-enabled services that guide drug development. The software segment includes platforms like Simcyp and Phoenix, which are considered industry standards for modeling drug behavior. The services segment provides the expert scientists who use this software to help clients with regulatory filings and market access strategies. Based on recent financials, gross margins sit at 58.1%, reflecting a mix of software scale and service labor.
Revenue by Geography
Who are its customers?
Certara serves a concentrated base of global pharmaceutical giants and over 2,300 biotechnology companies and regulatory agencies. The company's platform is utilized by all 20 of the top biopharmaceutical companies in the world based on R&D spend. While specific individual user counts are not disclosed, the company maintains a massive footprint across the industry with software licenses used in over 60 countries. Regulatory agencies including the FDA and the EMA also use Certara software to review the very drug applications that Certara's clients submit.
What gives it staying power?
Certara's software is deeply embedded in the regulatory approval process, creating incredibly high switching costs. Once a drugmaker uses a specific simulation model to justify a dosage to the FDA, they cannot easily switch to a different software without risking their regulatory timeline. This creates a standard that competitors find difficult to displace.
Where is it headed?
The company is aggressively pushing to move more of its business into software subscriptions rather than one-off service projects. Management is focusing on scaling the Simcyp platform into new areas like biologics and gene therapy. If this works, the business will see its profit margins expand significantly as software revenue requires very little extra cost to serve new customers.
Revenue has reached a steady double-digit growth path with 2024 sales hitting $390 million. While the business is not yet consistently profitable on a net income basis, the 11% annual growth shows consistent demand from the pharma sector.
Cash generation is the hidden strength of the business as free cash flow reached $80 million in 2024. This divergence from negative net income reveals that Certara is generating plenty of actual cash after paying for its operations. The capital-light nature of software means most of this cash can be reinvested into developing new simulation tools.
The balance sheet is exceptionally lean with a debt-to-equity ratio of only 0.01. Certara is carrying almost no debt, which gives the company massive flexibility to acquire smaller competitors or weather a downturn in R&D spending. This financial resilience is a major differentiator compared to other high-growth healthcare tech firms.
Certara is a cash-generative software business that is currently masking its true profitability by investing heavily in growth and product development.
The company's ability to turn revenue into cash is exceptional, with $80 million in annual free cash flow despite reported losses. This is driven by high gross margins of 58.1% and the upfront nature of software license payments. It proves the underlying unit economics of the software are healthy.
Net margins remain negative at -3.6%, showing that the company is still spending more on sales and development than it brings in. The primary risk is that this spending does not eventually lead to a shift in the revenue mix toward higher-margin software. Investors need to see the net margin move into positive territory over the next two years.
The biosimulation market is roughly $3B today and is growing at a double-digit pace as virtual trials replace expensive physical testing. The industry is on track to exceed $5B by 2028 as regulatory agencies increasingly require simulation data for drug approvals. Pricing power is structural because the cost of the software is a tiny fraction of the billions spent on drug development. Certara stands as the clear market leader in the specialized biosimulation niche, enjoying a massive runway as the industry digitizes.
The competitive dynamic in biosimulation is rationally structured with high barriers to entry due to the scientific expertise required. While broad healthcare tech is competitive, the specialized niche of regulatory-grade simulation is dominated by a few players with proven software. This leads to strong pricing power for established leaders.
Simulations Plus(SLP) is the most direct threat, attacking with a focused software suite for early-stage modeling. Schrodinger(SDGR) competes for the same R&D budgets but focuses on molecule discovery rather than the clinical trial modeling where Certara excels. The most dangerous threat is a shift by large clinical research organizations to build their own internal simulation tools.
Certara is holding its ground as the gold standard in the industry. The company maintains 100% penetration of the top 20 pharma companies, proving its competitive position is secure.
The primary source of protection for Certara is the incredibly high switching cost associated with regulatory-grade software. Once a drug's dosage and safety profile are established using Certara's Simcyp platform, switching to a competitor would require re-validating years of data. The 100% retention among top pharma leaders is the single most compelling proof of this moat.
The 58.1% gross margins and consistent $80 million in free cash flow prove that this advantage is durable. These numbers show a business that can generate significant cash despite being in a heavy investment phase. The high gross margin is consistent with a real moat that protects pricing even as the company scales.
The moat is strengthening as regulatory agencies like the FDA adopt Certara's software as their own internal review standard. This creates a "virtuous cycle" where drugmakers must use the same tools the regulators use.
Revenue grew 11% last year but net profitability remains negative.
Maintained strong FCF of $80M while keeping debt minimal.
Insider ownership is presence but no major recent open-market buys reported.
Capital Allocation Track Record
Management has shown they can grow the top line and generate cash, but they have yet to prove they can deliver consistent GAAP net profits. CEO Jon Resnick is successfully pivoting the company toward a software-first model which should eventually unlock higher margins. The financial discipline shown by maintaining a near-zero debt load is impressive for a growth-stage tech company.
© 2026 ClearThesis.ai · Report generated on May 27, 2026
This is an AI-generated analysis for informational purposes only and does not constitute financial advice. Data and analysis may not reflect recent developments if viewed significantly after the generation date. Always conduct your own due diligence before making any investment decisions.